TrianglePUBLICATIONS · 25231953
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2014 Dec
- First author
- Piccart M
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Piccart M
- type
- Author
- name
- Hortobagyi GN
- type
- Author
- name
- Campone M
- type
- Author
- name
- Pritchard KI
- type
- Author
- name
- Lebrun F
- type
- Author
- name
- Ito Y
- type
- Author
- name
- Noguchi S
- type
- Author
- name
- Perez A
- type
- Author
- name
- Rugo HS
- type
- Author
- name
- Deleu I
- type
- Author
- name
- Burris HA 3rd
- type
- Author
- name
- Provencher L
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Piccart M
- type
- Author
- name
- Hortobagyi GN
- type
- Author
- name
- Campone M
- type
- Author
- name
- Pritchard KI
- type
- Author
- name
- Lebrun F
- type
- Author
- name
- Ito Y
- type
- Author
- name
- Noguchi S
- type
- Author
- name
- Perez A
- type
- Author
- name
- Rugo HS
- type
- Author
- name
- Deleu I
- type
- Author
- name
- Burris HA 3rd
- type
- Author
- name
- Provencher L
- type
- Author
- bibliography ids
- nci-bib-a61c6a0a6b82096fea8e7ece
- book metadata
- content sha256
- 3ed16ffbc8e867ac8a577946312d617648933a32f669dc1587e717f5d1ae84de
- document type
- citation
- dois
- 10.1093/annonc/mdu456
- electronic publication date
- display
- 2014 Sep 17
- precision
- day
- year
- 2014
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:25231953
- immutable id
- pubmed:25231953@3ed16ffbc8e867ac8a577946312d617648933a32f669dc1587e717f5d1ae84de
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 12
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 2357-2362
- volume
- 25
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 25231953
- provenance
- batch id
- 69903be8ceab8801c81a
- provider
- NCBI PubMed ESummary
- record sha256
- adbb058e6157868a6a9cbd9a38ca933d2fdbe2b0a8221ec437e4b9c2cd292f8b
- response sha256
- 1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
- retrieved at
- 2026-09-09T23:47:05.208886+00:00
- publication date
- display
- 2014 Dec
- precision
- month
- year
- 2014
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Preserved source evidence · Not medical advice